Grail Stock Pauses After Rally on Mixed FDA Panel Vote for Cancer Test

Grail Inc. (GRAL) shares pulled back on Thursday after a significant rally, as investors weighed a positive but nuanced recommendation from a U.S. Food and Drug Administration advisory panel for its Galleri cancer-screening test. The stock's recent surge, which saw it gain 28.89% in one week, has brought valuation concerns to the forefront despite the favorable regulatory development.

FDA Panel Offers Measured Support

On September 23, an FDA advisory panel voted in favor of Grail's multi-cancer early detection test, Galleri. The panel's decision, however, was not uniformly decisive, highlighting potential hurdles ahead.

• Safety: The panel voted 10-0 that the test was safe.
• Risk/Benefit: It voted 7-2, with one abstention, that the test's benefits outweighed its risks.
• Effectiveness: The vote on effectiveness was a much narrower 6-4.

The panel also emphasized that Galleri should be used to supplement, not replace, existing cancer-screening standards. While the recommendation is a constructive step toward approval, the final FDA decision is still pending, and the narrow effectiveness vote could influence future labeling and commercial adoption.

Valuation and Commercial Hurdles

Ad

Following the news, analysts appear divided on the stock's future, reflecting uncertainty about its commercial potential. Baird raised its price target to $118, while Canaccord maintained a Buy rating but with a more modest $80 target. This divergence suggests that while the market acknowledges the regulatory progress, it is struggling to price in the economic value of future adoption.

Furthermore, a fair-value model from FinQL cited by Investing.com estimates Grail's intrinsic value at $67.53, implying significant downside from its September 24 price of $105.01. Key unresolved factors that will determine Galleri's commercial success include the final FDA-approved labeling, the extent of insurer reimbursement, and any post-approval study requirements.

Financials Underscore Risks

Grail's underlying financials present a mixed picture. The company reported revenue of $44.70 million in its most recent quarter, beating expectations. However, it also posted a net loss per share of $2.56 and, as of June 30, held $55.65 million in cash against $91.31 million in debt.

With the company not yet profitable, continued cash burn and the need for future financing could pose risks for investors. The stock has already priced in a largely positive regulatory outcome, and the focus will now shift to the company's ability to secure broad reimbursement and achieve commercial viability.